MeiraGTx Holdings plc
MGTXNasdaq
$12.44
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↑ +43.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.0B
Enterprise Value
$939.8M
P/E
—
P/S
12.7
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
0.4%
Dividend Yield
—
Revenue (TTM)
$79.8M
Net Income (TTM)
-$120.5M
Free Cash Flow (TTM)
$4.2M
Gross Margin
—
Operating Margin
-131.9%
Net Margin
-151.1%
ROE
207.4%
ROIC
—
Debt / Equity
—
Net Cash
$71.5M
Return 1Y
+44.3%
Company profile
MeiraGTx Holdings plc focuses on developing treatments for patients with serious diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop a gene therapy treatment using the company's proprietary riboswitch technology.
- CEO
- Alexandria Forbes
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 300
- Headquarters
- New York
- Website
- meiragtx.com
Management & directors
- Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGY
- Giroux RichardCFO & COO
- Forbes AlexandriaPRESIDENT & CEO
- Wollin Robert JGENERAL COUNSEL AND SECRETARY
- Zeldin Robert KCHIEF MEDICAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
MGTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$293,000.00↓ -84.8%
Diluted EPS-$0.57↑ +11.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $15.6M | $37.7M | $15.9M | $14.0M | $33.3M | $81.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$62.6M | -$72.8M | -$116.4M | -$137.1M | -$164.2M | -$106.0M |
| Net income | -$58.0M | -$79.6M | -$129.6M | -$84.0M | -$147.8M | -$114.2M |
| Diluted EPS | -$1.54 | -$1.80 | -$2.87 | -$1.49 | -$2.12 | -$1.42 |
| Operating cash flow | -$64.0M | -$10.5M | -$73.1M | -$105.4M | -$104.5M | -$46.4M |
| Free cash flow | -$84.9M | -$56.9M | -$118.1M | -$125.5M | -$109.5M | -$50.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -401.9% | -193.0% | -730.9% | -977.8% | -493.4% | -130.2% |
| Net margin | -372.6% | -211.0% | -814.2% | -599.5% | -444.1% | -140.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $282,000.00 | $10.9M | $21.4M | $1.9M | $3.7M | $410,000.00 | $75.4M | $293,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$45.9M | -$40.0M | -$31.5M | -$41.6M | -$44.8M | -$46.1M | $26.5M | -$40.8M |
| Net income | -$48.6M | -$39.3M | -$39.4M | -$40.0M | -$38.8M | -$50.5M | $15.1M | -$46.3M |
| Diluted EPS | -$0.76 | -$0.55 | -$0.49 | -$0.51 | -$0.48 | -$0.62 | $0.19 | -$0.57 |
| Operating cash flow | -$19.5M | -$25.0M | -$23.3M | -$36.8M | -$43.9M | -$12.2M | $46.6M | $17.8M |
| Free cash flow | -$20.8M | -$25.8M | -$24.5M | -$38.5M | -$45.2M | -$12.8M | $46.4M | $15.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -16279.8% | -367.0% | -147.2% | -2159.7% | -1213.6% | -11232.0% | 35.1% | -13930.7% |
| Net margin | -17241.1% | -360.5% | -184.2% | -2075.9% | -1051.1% | -12320.2% | 20.0% | -15806.5% |
Company news
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Naylor Stuart· CHIEF SCI OFCR, OPHTHALMOLOGY | Sale | 25,112 | $14.90 | $374,168.80 | filing |
| 2026-07-07 | Naylor Stuart· CHIEF SCI OFCR, OPHTHALMOLOGY | Sale | 2,547 | $13.86 | $35,301.42 | filing |
| 2026-06-10 | Harris Keith R. | Option exercise | 75,000 | — | — | filing |
| 2026-05-27 | Giroux Richard· CFO & COO | Gift | 7,000 | $0.00 | $0.00 | filing |
| 2026-05-19 | Forbes Alexandria· PRESIDENT & CEO | Sale | 62,000 | $9.17 | $568,540.00 | filing |
| 2026-04-21 | Giroux Richard· CFO & COO | Sale | 56,000 | $10.22 | $572,320.00 | filing |
| 2026-04-07 | Naylor Stuart· CHIEF DEV. OFFICER | Sale | 27,661 | $9.36 | $258,906.96 | filing |
| 2026-03-24 | Forbes Alexandria· PRESIDENT & CEO | Sale | 62,000 | $7.41 | $459,420.00 | filing |
| 2026-02-21 | Forbes Alexandria· PRESIDENT & CEO | Tax withholding | 33,048 | $7.45 | $246,207.60 | filing |
| 2026-02-21 | Giroux Richard· CFO & COO | Tax withholding | 31,726 | $7.45 | $236,358.70 | filing |
| 2026-02-21 | Naylor Stuart· CHIEF DEV. OFFICER | Tax withholding | 11,750 | $7.45 | $87,537.50 | filing |
| 2026-02-21 | Wollin Robert J· GENERAL COUNSEL AND SECRETARY | Tax withholding | 5,949 | $7.45 | $44,320.05 | filing |
| 2026-02-21 | Zeldin Robert K· CHIEF MEDICAL OFFICER | Tax withholding | 2,952 | $7.45 | $21,992.40 | filing |
| 2026-02-21 | Giroux Richard· CFO & COO | Option exercise | 60,000 | — | — | filing |
| 2026-02-21 | Zeldin Robert K· CHIEF MEDICAL OFFICER | Option exercise | 7,500 | — | — | filing |
| 2026-02-21 | Wollin Robert J· GENERAL COUNSEL AND SECRETARY | Option exercise | 11,250 | — | — | filing |
| 2026-02-21 | Naylor Stuart· CHIEF DEV. OFFICER | Option exercise | 25,000 | — | — | filing |
| 2026-02-21 | Forbes Alexandria· PRESIDENT & CEO | Option exercise | 62,500 | — | — | filing |
| 2026-01-17 | Giroux Richard· CFO & COO | Tax withholding | 163,916 | $7.42 | $1.2M | filing |
| 2026-01-17 | Forbes Alexandria· PRESIDENT & CEO | Tax withholding | 163,916 | $7.42 | $1.2M | filing |
| 2026-01-17 | Naylor Stuart· CHIEF DEV. OFFICER | Tax withholding | 35,250 | $7.42 | $261,555.00 | filing |
| 2026-01-17 | Wollin Robert J· GENERAL COUNSEL AND SECRETARY | Tax withholding | 27,206 | $7.42 | $201,868.52 | filing |
| 2026-01-17 | Zeldin Robert K· CHIEF MEDICAL OFFICER | Tax withholding | 13,951 | $7.42 | $103,516.42 | filing |
| 2026-01-17 | Zeldin Robert K· CHIEF MEDICAL OFFICER | Option exercise | 35,000 | — | — | filing |
| 2026-01-17 | Wollin Robert J· GENERAL COUNSEL AND SECRETARY | Option exercise | 50,000 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.